Oxford BioMedica Licenses Retroviral Ex Vivo Gene Delivery Technology to MolMed SpA
Oxford BioMedica and MolMed SpA (Milan, Italy) today announced a licence agreement for Oxford BioMedica's retroviral ex vivo gene delivery technology. The agreement provides MolMed with rights to utilise this technology in the development of MolMed's product pipeline. Under the agreement, Oxford BioMedica receives an upfront licence fee and annual maintenance payments. In addition, Oxford BioMedica will receive payments on the achievement of clinical and regulatory milestones by MolMed and product royalties. Further financial details were not disclosed.
The retroviral ex vivo gene delivery technology combines Oxford BioMedica's technology with some of the gene therapy technology acquired from Chiron Corporation in June this year.
Oxford BioMedica's CEO, Professor Alan Kingsman, said: "We are delighted to welcome MolMed to the list of Oxford BioMedica's technology licensees. This agreement provides further evidence of the breadth and strength of our proprietary gene delivery technology."
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.

Topic world Gene therapy
Genetic diseases once considered untreatable are now at the center of innovative therapeutic approaches. Research and development of gene therapies in biotech and pharma aim to directly correct or replace defective or missing genes to combat disease at the molecular level. This revolutionary approach promises not only to treat symptoms, but to eliminate the cause of the disease itself.